跳至主要内容
临床试验/NCT05949697
NCT05949697已完成不适用

A Prospective Study of the Dry Eye Drink by Bruder Healthcare That Evaluates Hydration and Subject's Assessment on Eye Dryness

Bruder Healthcare2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Change on the SPEED score

研究概览

简要总结

A study to assess the effect of the Dry Eye Drink on eye dryness

详细描述

This is a prospective, non-randomized, comparative study of the Dry Eye Drink by Bruder Healthcare that evaluates hydration and subject's assessment on eye dryness. Subjects will administer the Dry Eye Drink by adding one sachet of the Dry Eye Drink powder in 12 Oz of water.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and/or female subjects aged between 18 and 65 years (both limits inclusive).
  • Subjects with symptomatic Dry Eye Syndrome confirmed at baseline in at least any one or both the eyes.
  • Subjects with ≥ 310 mOsmol/L tear osmolarity.
  • Subjects with ≥ 6 SPEED score.
  • Subject willing to provide written informed consent and able to comply with protocol requirements.

排除标准

  • Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
  • Have undergone mechanical treatment for meibomian gland dysfunction using thermal pulsation/expression (e.g., LipiFlow) or intense pulsed light (e.g., OptiLight) therapy within 6 months prior to the Screening/Baseline Visit
  • Have a known hypersensitivity to any of the study product components
  • Have undergone ocular surgery (e.g., cataract, corneal or refractive surgical procedure) within 6 months prior to the Screening/Baseline Visit
  • Have evidence of clinically significant ocular trauma
  • Have active ocular Herpes simplex or Herpes Zoster infection
  • Have ocular inflammation (uveitis, iritis, scleritis, episcleritis, conjunctivitis or keratitis, with the exception of keratoconjunctivitis sicca) at the discretion of the investigator
  • Have ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids. including hordeolum)
  • Have severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
  • Have eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis)
  • Have an ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity)
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Participation in any clinical study within 30 days before the first administration of study product.
  • Subjects who are illiterate and cannot complete the subject diary independently.

结局指标

主要结局

Change on the SPEED score

时间窗: Day 0 and Day 30

Change on the subjects' perception of eye dryness from Baseline to end of treatment as assessed by Standard Patient Evaluation of Eye Dryness (SPEED) score

次要结局

  • Change in MMP-9 levels(Day 0 and Day 30)
  • Change in Tear Osmolarity(Day 0 and Day 30)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验